Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 595 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... October 31, 2024 Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive... July 8, 2026 New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... December 5, 2019 Load more HOT NEWS The incredible value of going public Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over... Talking About Your Sexual Orientation and Gender Identity With Your Cancer... ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3...
